Quick Answer
Prelude Therapeutics Inc reported Total Assets of $141.32 million for the year ending 2025.
- Prelude Therapeutics Inc showed a decrease of -19.5% in Total Assets from 2024 to 2025.
- This data is from Prelude Therapeutics Inc's annual report (Form 10-K), filed with the SEC on March 10, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2020: $239.68 million | Q1 2021: $369.83 million | Q2 2021: $349.58 million | Q3 2021: $331.22 million | Q1 2022: $280.67 million | Q2 2022: $259.06 million | Q3 2022: $242.33 million | Q1 2023: $198.32 million | Q2 2023: $280.61 million | Q3 2023: $258.51 million | Q1 2024: $247.11 million | Q2 2024: $224.29 million | Q3 2024: $197.22 million | Q1 2025: $141.26 million | Q2 2025: $114.92 million | Q3 2025: $94.76 million.
- Over the full 7 years of available data (2019 to 2025), Prelude Therapeutics Inc's Total Assets has grown by 546.1%.
- Historical annual values: Fiscal year 2025: $141.32 million | Fiscal year 2024: $175.52 million | Fiscal year 2023: $277.67 million | Fiscal year 2022: $220.50 million | Fiscal year 2021: $305.10 million | Fiscal year 2020: $223.59 million | Fiscal year 2019: $21.87 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: